Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USA
October 24, 2017 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor in hematological...
Surefire Receives Regulatory Approval for Infusion Systems and Guiding Catheters in Mexico
March 20, 2017 06:00 ET | Surefire Medical, Inc.
WESTMINSTER, Colo., March 20, 2017 (GLOBE NEWSWIRE) -- Surefire Medical, Inc., the developer of site-specific delivery devices for the Interventional Oncology market, announced today that the...
Kura Oncology to Present at the Jefferies 2015 Global Healthcare Conference
May 27, 2015 07:30 ET | Kura Oncology, Inc.
LA JOLLA, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and...